Table 2.
Summary of the 2 large prospective observational studies of sorafenib for treatment of unresectable hepatocellular carcinoma
|
Ref.
|
No. of patients (Child-Pugh A or Child-Pugh B)
|
Treatment
|
Median OS in mo
|
Response rate, %
|
Control rate, %
|
Median TP in mo
|
Dose reduction, % patients
|
Discontinuation due to AE, % patients
|
| Abou-Alfa et al[68] | 98 | Sorafenib (400 mg × 2/d) | 10.7 | 2 | 43 | 5.5 | 26 | 11 |
| 38 | Sorafenib (400 mg × 2/d) | 7.9 | 1 | 32 | 2.8 | 7 | 5 | |
| Cheng et al[34] (Asia-Pacific) | 150 (146/4) | Sorafenib (400 mg × 2/d) | 6.5 | 3.3 | 35.3 | 5.5 | 30.9 | 19.5 |
| 76 (74/2) | Placebo | 4.2 | 1.3 | 15.8 | 2.8 | 2.7 | 13.3 |
AE: Adverse event; OS: Overall survival; TP: Time to progression.